CLDN1 and gastric cancer: Use of monoclonal antibodies for claudin targeting led to very promising in vivo results; in particular with anti-Cldn18 or -Cldn1 antibodies for treatment of gastric cancer or HCV infections, respectively [14,18,32,33,56,57].